Short Interest in Exicure, Inc. (NASDAQ:XCUR) Increases By 24.2%

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 28,200 shares, a growth of 24.2% from the February 13th total of 22,700 shares. Currently, 7.4% of the company’s shares are sold short. Based on an average daily volume of 106,200 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of Exicure

A hedge fund recently raised its stake in Exicure stock. Carlyle Group Inc. grew its stake in shares of Exicure, Inc. (NASDAQ:XCUR) by 400.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 281,636 shares of the company’s stock after purchasing an additional 225,308 shares during the quarter. Exicure makes up approximately 0.9% of Carlyle Group Inc.’s investment portfolio, making the stock its 11th largest position. Carlyle Group Inc. owned approximately 10.79% of Exicure worth $3,850,000 as of its most recent filing with the Securities and Exchange Commission. 42.82% of the stock is currently owned by institutional investors.

Exicure Trading Up 1.2 %

Shares of XCUR opened at $12.99 on Tuesday. The firm has a market capitalization of $33.85 million, a P/E ratio of -6.28 and a beta of 3.84. Exicure has a 12-month low of $1.44 and a 12-month high of $36.00. The firm has a fifty day moving average price of $10.28 and a 200-day moving average price of $9.31.

About Exicure

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.